Cybin Investor Relations

Cybin is a biotech company advancing psychedelic pharmaceutical treatments. Toronto (NEO: CYBN) and OTC (CLXPF), IR email: [email protected]

[Cybin Investor Relations @CybinIr]

$CYBN Announces Grant of U.S. Patent for the Treatment of Anxiety Disorders https://t.co/3HFHCcxj3e #psilocybin $ATAI $CMPS

[Cybin Investor Relations @CybinIr]

$CYBN Institutional Review Board Grants Approval for Cybin-Sponsored Feasibility Study Using Kernel Flow Technology to Measure Psychedelic Effects on the Brain https://t.co/ThcVBwJ1Ss #psilocybin #MDD

[Cybin Investor Relations @CybinIr]

$CYBN webcast at HC Wainwright Bioconnect conference today available now https://t.co/D4U3zDPm0f #psilocybin https://t.co/RwKOrcuVys

[Cybin Investor Relations @CybinIr]

$CYBN Cybin Awarded Notice of Allowance from U.S. Patent and Trademark Office for CYB004 (Deuterated Psychedelic Tryptamine) for the Treatment of Anxiety Disorders https://t.co/LFA4mjmhPa $CMPS $GHRS #psilocybin

[Cybin Investor Relations @CybinIr]

$CYBN Confirms Scientific Advice Meeting with UK Medical and Healthcare Products Regulatory Agency for Lead Candidate CYB003 for the Treatment of Major Depressive Disorder and Alcohol Use Disorder https://t.co/wBkjHIL0vS #psilocybin #psychedelics

[Cybin Investor Relations @CybinIr]

$CYBN webcast tomorrow at 3:30pm $GHRS #psilocybin #psychedelics https://t.co/VvFzIf9Ove

[Cybin Investor Relations @CybinIr]

Fireside chat with $CYBN CEO Doug Drysdale at H.C. Wainwright 2nd Annual #Psychedelics Conference available now https://t.co/PKfNxDQqm2

[Cybin Investor Relations @CybinIr]

$CYBN webcast at 3:30pm EST on 12/8 at Stifel GMP 2nd Annual Future of Healthcare Conference https://t.co/eFsG2FXRqZ #psilocybin $CMPS $GHRS $BIIB $SAGE $BTAI #psychedelics

[Cybin Investor Relations @CybinIr]

$CYBN to Participate in the H.C. Wainwright 2nd Annual #Psychedelics Conference on December 6 https://t.co/ZsR8CHWm07 Fireside Chat with CEO Doug Drysdale available on demand beginning at 7am EST $CMPS $ATAI

[Cybin Investor Relations @CybinIr]

$CYBN Cybin Announces Additional Adelia Milestone Achievements
https://t.co/Rg0QrwZZ3Z "Psychedelics to Therapeutics™" #psilocybin $CMPS $ATAI

[Cybin Investor Relations @CybinIr]

$CYBN Awards Grant for Psychedelic Treatment Clinic at Lenox Hill Hospital https://t.co/TFBe68VM7a @NorthwellHealth

[Cybin Investor Relations @CybinIr]

$CYBN A Conversation With Cybin Chief Clinical Officer Dr. Alex Belser https://t.co/yVVQCSFD27 #Psychedelics $CMPS

[Cybin Investor Relations @CybinIr]

$CYBN Reports its Second Quarter Financial Results with Webcast Today 11/15/21 at 4:30pm EST #psilocybin
https://t.co/enWqBiYMoJ

[Cybin Investor Relations @CybinIr]

Cantor Fitzgerald Initiates Coverage On $CYBN with Overweight Rating, Announces Price Target of $9 https://t.co/CyyiXOa5kQ #psilocybin @Benzinga

[Cybin Investor Relations @CybinIr]

$CYBN @Benzinga interviews CEO Doug Dysdale as Cybin Becomes First #Psychedelics Company On The @NYSE https://t.co/NA3sN6VpCr #psilocybin

[Cybin Investor Relations @CybinIr]

$CLXPF Cybin to Commence Trading on the NYSE American on August 5 under the symbol CYBN #psilocybin https://t.co/htkrE0HVOV

[Cybin Investor Relations @CybinIr]

$CLXPF Cybin to Commence Trading on the NYSE American on August 5 under symbol CYBN #psilocybin https://t.co/bhqZaHLeJK

[Cybin Investor Relations @CybinIr]

$CLXPF Cybin Announces Closing of Public Offering of Common Shares and Exercise of Over-Allotment Option for total gross proceeds of CAD 34,501,840 https://t.co/HJW6NIHJmT #psilocybin @Benzinga $CMPS $ATAI $FTRPF

[Cybin Investor Relations @CybinIr]

@Benzinga #Psyched today features $CLXPF $MNMD $LKYSF #psilocybin @michaelpollan @PetrieFlom https://t.co/nVFvW7xtyq

[Cybin Investor Relations @CybinIr]

$CLXPF Cybin to Participate in Cowen’s Psychedelics & Novel Mechanisms in Neuropsychiatry Virtual Summit on July 13th $CMPS $ATAI https://t.co/uniBaepEnt